Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Non-Current Assets (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Other Non-Current Assets data on record, last reported at $266000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 8766.67% year-over-year to $266000.0; the TTM value through Sep 2025 reached $266000.0, up 8766.67%, while the annual FY2024 figure was $3000.0, 99.77% down from the prior year.
  • Other Non-Current Assets reached $266000.0 in Q3 2025 per CTNM's latest filing, up from $186000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.6 million in Q1 2024 and bottomed at $3000.0 in Q2 2024.
  • Average Other Non-Current Assets over 3 years is $546375.0, with a median of $95000.0 recorded in 2025.
  • The widest YoY moves for Other Non-Current Assets: up 8766.67% in 2025, down 99.85% in 2025.
  • A 3-year view of Other Non-Current Assets shows it stood at $1.3 million in 2023, then plummeted by 99.77% to $3000.0 in 2024, then soared by 8766.67% to $266000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $266000.0 in Q3 2025, $186000.0 in Q2 2025, and $4000.0 in Q1 2025.